NCT07252739
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07252739
Title KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Acronym MK-3475-01J/KEYMAKER-U01J
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme LLC
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Clermont Oncology Center ( Site 0041) RECRUITING Clermont Florida 34711 United States Details
Communal Noncommercial Enterprise "Podillia Regional Oncolog-Cardiothoracic department ( Site 0131) RECRUITING Vinnitsya Vinnytsia Oblast 21029 Ukraine Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field